Burden of metastatic bone disease from genitourinary malignancies

References

• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res.12(20 Pt 2), 6243S–6249S (2006).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol.21(16), 3150–3157 (2003).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94(19), 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Kinnane N. Burden of bone disease. Eur. J. Oncol. Nurs.11(Suppl. 2), S28–S31 (2007).
   Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer110(8), 1860–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol.16(4), 579–584 (2005).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl Cancer Inst.95(17), 1300–1311 (2003).
   PubMed Web of Science ®Google Scholar
• Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J. Urol.170(6 Pt 2), S55–S57 (2003).
   Google Scholar
• Basch EM, Somerfield MR, Beer TM et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J. Clin. Oncol.25(33), 5313–5318 (2007).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur. Urol.53(1), 68–80 (2008).
   PubMed Web of Science ®Google Scholar
• Kataja VV. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann. Oncol.14(7), 1010–1011 (2003).
   PubMedGoogle Scholar
• Mohler J, Babaian RJ, Bahnson RR et al. Prostate cancer. Clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw.5(7), 650–683 (2007).
   PubMedGoogle Scholar
• Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol.19(3), 420–432 (2008).
   PubMed Web of Science ®Google Scholar
• Weissbach L. [Diagnostic work-up of bone metastases of genitourinary tumors and their treatment with bisphosphonates. Interdisciplinary consensus conference, Frankfurt, 2006]. Urologe A45(12), 1527–1531 (2006).
   PubMedGoogle Scholar
• Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J. Support. Oncol.2(3), 205–213 (2004).
   PubMedGoogle Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer2(8), 584–593 (2002).
   PubMed Web of Science ®Google Scholar
• Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int. J. Oncol.19(2), 379–382 (2001).
   PubMed Web of Science ®Google Scholar
• Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur. Urol.49(3), 429–440 (2006).
   PubMed Web of Science ®Google Scholar
• Goldman SM, Fajardo AA, Naraval RC, Madewell JE. Metastatic transitional cell carcinoma from the bladder: radiographic manifestations. AJR Am. J. Roentgenol.132(3), 419–425 (1979).
   PubMedGoogle Scholar
• Rajarubendra N, Bolton D, Lawrentschuk N. Diagnosis of bone metastases in urological malignancies – an update. Urology76(4), 782–790 (2010).
   PubMedGoogle Scholar
• Lecouvet FE, Geukens D, Stainier A et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost–effectiveness and comparison with current detection strategies. J. Clin. Oncol.25(22), 3281–3287 (2007).
   PubMed Web of Science ®Google Scholar
• Traill ZC, Talbot D, Golding S, Gleeson FV. Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases. Clin. Radiol.54(7), 448–451 (1999).
   PubMed Web of Science ®Google Scholar
• Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br. J. Cancer101(8), 1225–1232 (2009).
   PubMedGoogle Scholar
• Rublee DA. Medical technology in Canada, Germany, and the United States: an update. Health Aff. (Millwood)13(4), 113–117 (1994).
   PubMedGoogle Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev.27(3), 165–176 (2001).
   PubMed Web of Science ®Google Scholar
• Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int. J. Clin. Oncol.15(4), 382–389 (2010).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96(11), 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Mulders PF, Miller K, Tchekmedyian NS, Chen Y. Long-term reduction of skeletal complications with zoledronic acid in patients with advanced renal cell carcinoma or bladder cancer. Presented at: 22nd Annual EAU Congress. Berlin, Germany, 21–24 March 2007 (Abstract 971).
   Google Scholar
• Saad F, Gleason D, Murray R et al. Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases. Presented at: 19th Annual EAU Congress. Vienna, Austria, 24–27 March 2004 (Abstract 615).
   Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J.7(5), 377–387 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support. Cancer Ther.4(2), 92–100 (2007).
   PubMedGoogle Scholar
• Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.60(5), 1373–1378 (2004).
   PubMed Web of Science ®Google Scholar
• Fitch M, Maxwell C, Ryan C, Lothman H, Drudge-Coates L, Costa L. Bone metastases from advanced cancers: clinical implications and treatment options. Clin. J. Oncol. Nurs.13(6), 701–710 (2009).
   PubMed Web of Science ®Google Scholar
• Inoue T, Segawa T, Kamba T et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology73(5), 1104–1109 (2009).
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br. J. Cancer88(2), 195–201 (2003).
   PubMedGoogle Scholar
• DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support. Care Cancer15(7), 869–876 (2007).
   PubMed Web of Science ®Google Scholar
• Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol.26(15), 2544–2549 (2008).
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual. Life Res.15(8), 1297–1306 (2006).
   PubMed Web of Science ®Google Scholar
• Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer94(10), 2521–2533 (2002).
   PubMed Web of Science ®Google Scholar
• Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat. Rev.34(2), 183–192 (2008).
   PubMed Web of Science ®Google Scholar
• Henry D, Von Moos R, Vadhan-Raj R et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at: Joint ECCO 15–34th ESMO Multidisciplinary Congress. Berlin, Germany, 20–24 September 2009 (Abstract 20LBA).
   Google Scholar
• Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin. Oncol.34(6 Suppl. 4), S17–S23 (2007).
   PubMed Web of Science ®Google Scholar
• Piga A, Bracci R, Ferretti B et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J. Exp. Clin. Cancer Res.17(2), 213–217 (1998).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol.165(1), 136–140 (2001).
   PubMed Web of Science ®Google Scholar
• Hering F, Rodrigues PR, Lipay M. Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int. Braz. J. Urol.29(3), 228–233 (2003).
   PubMedGoogle Scholar
• Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J. Clin. Oncol.21(17), 3335–3342 (2003).
   PubMed Web of Science ®Google Scholar
• Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol.21(23), 4277–4284 (2003).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis.5(3), 231–235 (2002).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Yanagihara RH, Wood AJ et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist9(6), 687–695 (2004).
   PubMedGoogle Scholar
• Efstathiou E, Bozas G, Kostakopoulos A et al. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology65(1), 126–130 (2005).
   PubMed Web of Science ®Google Scholar
• Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer98(5), 962–969 (2003).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol.10(9), 872–876 (2009).
   PubMed Web of Science ®Google Scholar
• Saad F, Eastham J, Chin J. Benefits of zoledronic acid in patients with bone metastases from prostate cancer who have early bone disease. Presented at: ASCO 2007 Prostate Cancer Symposium. Orlando, FL, USA, 22–24 February 2007 (Abstract 234).
   Google Scholar
• Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J. Urol.141(1), 85–87 (1989).
   PubMed Web of Science ®Google Scholar
• Adami S, Salvagno G, Guarrera G et al. Dichloromethylene–diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol.134(6), 1152–1154 (1985).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with castration-resistant prostate cancer. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 4–8 June 2010 (Abstract LBA4507).
   Google Scholar
• Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer113(1), 193–201 (2008).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized Phase II trial. J. Urol.182(2), 509–515 (2009).
   PubMed Web of Science ®Google Scholar
• Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur. Urol.43(3), 226–232 (2003).
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am. J. Manag. Care14(5), 317–322 (2008).
   PubMed Web of Science ®Google Scholar
• Reed SD, Radeva JI, Glendenning GA, Saad F, Schulman KA. Cost–effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J. Urol.171(4), 1537–1542 (2004).
   PubMed Web of Science ®Google Scholar
• Botteman MF, Kaura S. Zoledronic acid is cost saving and improves quality-adjusted survival in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma (RCC): a United Kingdom (UK) perspective. Presented at: 23rd Annual EAU Congress. Milan, Italy, 26–29 March 2008 (Abstract 950).
   Google Scholar
• Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist12(12), 1404–1415 (2007).
   PubMed Web of Science ®Google Scholar
• Bukowski R, Elsen TE, Stadler WM et al. Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the Phase III TARGET study. Presented at: Joint ECCO 15–34th ESMO Multidisciplinary Congress. Berlin, Germany, 20–24 September 2009 (Abstract P-7130).
   Google Scholar
• Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int.96(7), 964–969 (2005).
   PubMed Web of Science ®Google Scholar
• Kijima T, Fujii Y, Suyama T et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int.103(5), 620–624 (2009).
   PubMedGoogle Scholar
• Tannir N, Jonasch E, Pagliaro LC et al. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma. Cancer107(3), 497–505 (2006).
   PubMedGoogle Scholar
• Abrahamsson PA, Ostri P, Andersen M, Kruger Hagen E. Nordic observational study evaluating safety and analgesic consumption in patients with advanced cancer under zoledronic acid (ZOMETA®) treatment: NOSAZ – interim analysis. Presented at: 23rd Annual EAU Congress. Milan, Italy, 26–29 March 2008 (Abstract 645).
   Google Scholar
• Miwa S, Mizokami A, Konaka H, Izumi K, Nohara T, Namiki M. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn. J. Clin. Oncol.39(11), 745–750 (2009).
   PubMedGoogle Scholar
• Hird AE, Chow E, Ehrlich L et al. Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature. J. Palliat. Med.11(8), 1156–1161 (2008).
   PubMedGoogle Scholar
• Prout GR Jr, Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer43(6), 2532–2539 (1979).
   PubMed Web of Science ®Google Scholar
• Lipton A. The safety of zoledronic acid. Expert Opin. Drug Saf.6(3), 305–313 (2007).
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res.23(6), 826–836 (2008).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol.20(1), 117–120 (2009).
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol.20(1), 137–145 (2009).
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu. Rev. Med.60, 85–96 (2009).
   PubMed Web of Science ®Google Scholar